Methods: ETV-treated patients completing ETV-022 or ETV-027 received ETV (1.0mg daily) in ETV-901. Primary endpoints included 2-point decrease in Knodell necroinflammatory score, no worsening of Knodell fibrosis score and improvement in Ishak fibrosis score (IFS) ( 1-point decrease) vs. baseline. Secondary endpoints included proportions with HBV DNA<300 copies/mL, ALT normalization, and IFS normalization in patients with advanced fibrosis/cirrhosis. Results: Quasi-perfect concordance (> 99.6%) was obtained between the two assays for the samples tested. No indeterminate results were observed. For one sample, LiPA provided additional information (wild-type/mutant mix), whereas sequencing showed only wild type. For sequential samples, LiPA was clearly able to detect emerging treatment-resistance mutations associated with viral breakthrough.